Unregulated Solutions, Unseen Dangers
Every day, millions seek online solutions for age-old anxieties like hair loss. The ads blanket podcasts, Instagram feeds, and primetime TV — telehealth brands promising “scientifically proven” results, shipped discreetly after a few clicks. But this digital convenience, marketed as liberation from stigma and slow in-person appointments, may be exposing Americans to unexpected and potentially life-altering dangers.
This week, the U.S. Food and Drug Administration (FDA) fired a warning shot heard across the booming telehealth and compounding pharmacy industry. It addressed a surge in adverse events linked to topical finasteride products — creams or sprays promoted for hair restoration by big-name online providers like Hims, Keeps, and Ro. The FDA highlights a simple yet stunning fact: No topical version of finasteride is FDA-approved for hair loss. Only the pill, under the brand names Proscar or Propecia, has gone through the thorough clinical vetting we expect for any drug that can alter our bodies at the cellular level.
So how have Americans ended up with compounded, custom-mixed sprays and gels—advertised as safe and effective—delivered to their mailboxes with minimal oversight? It’s a byproduct of two intersecting trends: the explosive growth of online health platforms exploiting regulatory grey zones, and the ever-present vulnerability consumers feel around self-image and aging.
Side Effects in the Shadows: Stories Telehealth Won’t Tell You
Reports reviewed by the FDA describe consequences far more severe than a mere skin rash. According to the agency’s public alert, 32 adverse events involving compounded topical finasteride were reported between 2019 and 2024. The cases include sexual dysfunction, testicular pain, depression, anxiety — and even suicidal thoughts. Some patients described persistent symptoms that lingered long after stopping treatment, echoing the disturbing stories long associated with oral finasteride in certain individuals.
In one wrenching documented case, U.S. Army Sergeant Mark Millich turned to a topical finasteride product marketed by a telehealth platform. He reported not only sexual dysfunction, but also visible genital shrinkage and altered shape — symptoms that, according to The Wall Street Journal, persisted and profoundly impacted his well-being. “I wasn’t adequately warned,” Millich said, exemplifying a common grievance among patients who trusted the efficiency of virtual medicine.
The FDA’s warning also sheds light on a crucial, often-unspoken risk unique to topical medications—the ease of unintentional exposure to others. The lack of a protective drug coating, unlike oral tablets, means the active compound can transfer from skin to skin. This carries dangerous implications for pregnant women and children, groups especially susceptible to hormonal disruptors. The FDA specifically urged health care providers to educate patients on this hazard — but how well is that message getting through when treatment begins and ends with an impersonal app?
“Our health system must value patient safety over profit. Anything less is a disservice to those we’re meant to protect.”
Beyond that, the reported side effects only tell part of the story. Many who take advantage of direct-to-consumer options may never know to formally report adverse experiences. A closer look reveals the reporting system is likely capturing just a fraction of the harm — and disproportionately among patients who advocate for themselves or happen to recognize subtle symptoms as drug-induced.
Profit-Driven Medicine and the Problem with Digital Disruption
Why are unapproved, risky formulations reaching consumers at all? The answer exposes troubling priorities in the rapidly evolving telehealth industry. According to a former Hims physician, Dr. Jonathan Daly, the company’s culture prioritized maximizing prescription volume over rigorous patient evaluation. “It was about volume, not individualized care,” Daly told The Wall Street Journal. This echoes criticism from health policy experts who caution that the desire to streamline and scale healthcare can sometimes erode the guardrails that make medicine safe.
Traditional pharmaceutical manufacturers must disclose possible side effects prominently and submit comprehensive safety data before seeking approval. Telehealth companies, operating under a patchwork of regulations, often bypass these requirements. As a result, they aren’t compelled to trumpet risks in ads, though small print disclosures may reside somewhere on their websites. Is it a surprise, then, that so many patients remain unaware of what they’re really signing up for?
Harvard researcher and public health ethicist Dr. Lisa Schwartz warns, “The allure of digital convenience must not overtake longstanding standards set to protect patients. We must demand that these new players play on the same ethical field as traditional healthcare.” Regulatory gaps that favor efficiency and profit over caution can leave well-meaning consumers exposed—with the public paying the price when adverse outcomes arise.
Lessons Unlearned: When Deregulation Trumps Safety
The controversies swirling around topical finasteride echo past public health crises, when insufficient oversight and aggressive marketing clashed with patient welfare. Decades ago, diethylstilbestrol (DES) was prescribed to millions before its devastating side effects emerged. The opioid epidemic saw pharmaceutical companies dismiss warnings of addiction risks for the sake of market dominance. Government inaction and holes in federal regulation often magnify risks that disproportionately impact the most vulnerable: young people, women, and those who—lured by convenience and stigma-free care—trust new medical models over in-person oversight.
This pattern exposes a fundamental clash between two visions of medicine: one rooted in deliberate, data-driven safeguards and another in algorithmic, for-profit expediency. Progressive values demand health systems that serve collective well-being, not just individual consumer choice or entrepreneurial triumph. Diverse populations and those living in medical deserts may benefit from the promise of telehealth, but at what cost if basic patient protections are ignored?
Policymakers, consumer advocates, and health providers have an urgent responsibility to address this regulatory gap. According to a recent Pew Research study, 67% of Americans value robust government oversight of medication safety. The FDA’s warning is a wake-up call — not only for those desperately seeking hair regrowth, but for our entire society’s approach to innovation versus public protection.
Charting a Safer Path Forward
Should you or a loved one consider a telemedicine solution for hair loss, ask tough questions. What clinical data supports this product? Has it been vetted by the FDA? Are all side effects communicated clearly, or does the fine print hide critical information?
Real progress means harnessing technology’s power without abandoning the fundamental social contract at the heart of medicine: first, do no harm. There is room for innovation and inclusion, but not at the cost of transparency, oversight, and patient safety. Our health, self-worth, and trust in medical progress shouldn’t be sold to the highest bidder or compromised by deregulation. The standard we demand for ourselves must extend to everyone—across platforms, providers, and profit models alike.
